Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits
- PMID: 1992130
- DOI: 10.1021/jm00105a046
Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits
Abstract
Probucol (1) and probucol analogues with the substitutions at the disulfide-linked carbon (2, 3) and an additional substitution at a tert-butyl of each phenolic ring (4) were tested for their ability to lower total serum cholesterol and prevent aortic atherosclerosis in modified Watanabe heritable hyperlipidemic (WHHL) rabbits and to inhibit Cu2(+)-induced lipid peroxidation of isolated plasma low-density lipoproteins (LDL). After 84 days of feeding 1% of each compound in rabbit chow, probucol was effective in lowering serum cholesterol, whereas 2-4 were not. The concentration of drug in serum and LDL was 2 greater than 1 greater than 3 greater than 4. Probucol and analogues prevented Cu2(+)-induced oxidation of LDL in vitro to an extent that directly related to their concentrations in LDL. The decrease in lipid oxidation was directly correlated with the inhibition of both oxidized-LDL-induced cholesteryl ester synthesis in cultured macrophages and to the inhibition of aortic atherosclerosis in vivo. These results show that the antioxidant activity of probucol and analogues is directly related to their concentration in LDL, which may explain their pharmacological activity in reducing atherosclerosis.
Similar articles
-
Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.Atherosclerosis. 1999 Jan;142(1):169-78. doi: 10.1016/s0021-9150(98)00234-2. Atherosclerosis. 1999. PMID: 9920518
-
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31. doi: 10.1073/pnas.84.16.5928. Proc Natl Acad Sci U S A. 1987. PMID: 3475709 Free PMC article.
-
The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.Atherosclerosis. 1999 Jun;144(2):343-55. doi: 10.1016/s0021-9150(99)00002-7. Atherosclerosis. 1999. PMID: 10407495
-
[Probucol treatment of hyperlipidemia].Nihon Rinsho. 1994 Dec;52(12):3279-84. Nihon Rinsho. 1994. PMID: 7853723 Review. Japanese.
-
Where are we with probucol: a new life for an old drug?Atherosclerosis. 2009 Nov;207(1):16-23. doi: 10.1016/j.atherosclerosis.2009.04.002. Epub 2009 Apr 11. Atherosclerosis. 2009. PMID: 19457483 Review.
Cited by
-
Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging.J Exp Med. 2006 Apr 17;203(4):1117-27. doi: 10.1084/jem.20052321. Epub 2006 Apr 10. J Exp Med. 2006. PMID: 16606673 Free PMC article.
-
Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.Br J Pharmacol. 1996 Mar;117(6):1155-62. doi: 10.1111/j.1476-5381.1996.tb16710.x. Br J Pharmacol. 1996. PMID: 8882610 Free PMC article.
-
Ascorbate and phenolic antioxidant interactions in prevention of liposomal oxidation.Lipids. 1992 Jul;27(7):543-50. doi: 10.1007/BF02536138. Lipids. 1992. PMID: 1453885
-
Why are low-density lipoproteins atherogenic?West J Med. 1994 Feb;160(2):153-64. West J Med. 1994. PMID: 8160466 Free PMC article. Review.
-
Adriamycin-induced heart failure: mechanism and modulation.Mol Cell Biochem. 2000 Apr;207(1-2):77-86. doi: 10.1023/a:1007094214460. Mol Cell Biochem. 2000. PMID: 10888230 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical